At the time of licensing, the compound, then known as OWL833, was considered Phase I-ready for studies in type 2 diabetes
Funding This work was supported by National Key R&D Program of China (2019YFA0906100 and 2021YFC3300101), National Natural Science Foundation of China (82071772), Guangdong Basic and Applied Basic Research Foundation (2022A1515010070), Shenzhen Basic Science Research Project (JCYJ20220818102018038, JCYJ20220531095612029, JSGGZD20220822100005011), Shenzhen Medical Research Fund (A2301047), and Futian Healthcare Research Project (FTWS2023066)
Exendin(939) itself did not affect glucagon secretion at 1 mmol/l glucose (Fig
Research-grade online vendors that ship lab-tested vials for research use
The abdomen typically provides the most consistent absorption for subcutaneous injections, though all approved sites are clinically effective when proper technique is used